Q3 Earnings Forecast for Journey Medical Issued By B. Riley

Key Points

• B. Riley has revised its Q3 2025 earnings forecast for Journey Medical, now estimating earnings of ($0.01) per share, an improvement from the previous estimate of ($0.02).
• Journey Medical reported a Q2 loss of ($0.16) EPS, missing the consensus estimate of ($0.07) EPS, with a revenue of $15.01 million surpassing estimates.
• The stock price of Journey Medical has declined 4.3% recently, with a current trading price around $6.95 and a 52-week range between $3.54 and $8.90.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at B. Riley increased their Q3 2025 earnings per share estimates for shares of Journey Medical in a report issued on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.01) per share for the quarter, up from their previous estimate of ($0.02). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's Q4 2025 earnings at $0.06 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.29 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%. The company had revenue of $15.01 million during the quarter, compared to the consensus estimate of $14.93 million.

Other research analysts also recently issued research reports about the company. Lake Street Capital raised their target price on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Finally, Wall Street Zen downgraded Journey Medical from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th.

Journey Medical Stock Down 4.3%

Shares of NASDAQ DERM opened at $6.95 on Monday. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.90. The business has a 50-day simple moving average of $7.15 and a two-hundred day simple moving average of $6.54. The company has a quick ratio of 0.95, a current ratio of 1.27 and a debt-to-equity ratio of 1.11. The company has a market cap of $161.94 million, a P/E ratio of -18.29 and a beta of 0.80.

Institutional Trading of Journey Medical

Several institutional investors and hedge funds have recently modified their holdings of DERM. Dimensional Fund Advisors LP purchased a new stake in shares of Journey Medical in the 4th quarter valued at about $80,000. Kovitz Investment Group Partners LLC raised its holdings in shares of Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after acquiring an additional 13,105 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Journey Medical in the 4th quarter valued at about $174,000. Cetera Investment Advisers raised its holdings in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares in the last quarter. Finally, Tang Capital Management LLC purchased a new position in shares of Journey Medical during the 4th quarter valued at about $6,747,000. Hedge funds and other institutional investors own 7.25% of the company's stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.